Severe Covid-19 Clinical Trial
Official title:
Safety and Efficacy of Drugs Given Off-label for COVID-19
We performed a quasi-experimental open-label pragmatic study alternating standard of care (SOC) and oral bedtime melatonin (OBM) at different high doses over 4 consecutive time periods enrolling all consecutive RT-PCR SARS-CoV-2 severe Covid-19 admissions.
The 4 successive study time periods spanned from March 2020 to April 2021 and included: 1) standard of care (SOC) (C1), 2) SOC + oral bedtime melatonin (OBM) (T1), 3) SOC (C2), and 4) SOC + OBM (T2). During T1, 3 consecutive subgroups received 50 mg, 100 mg and 200 mg OBM. During T2, 100 mg OBM was given. Melatonin was administered from ICU admission to hospital discharge or death. The main objectives were occurrence of predefined severe adverse events (SAEs), Sequential Organ Failure Assessment (SOFA) scores and day-30 (D30) and 90 (D90) mortality. Study subjects were followed for modified Rankin scale (mRS) at 30 days after the last OBM dose or hospital discharge. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05175833 -
Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19
|
Phase 2 | |
| Recruiting |
NCT05256511 -
COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
|
||
| Completed |
NCT04866082 -
Corticosteroids in Severe COVID-19 (ASAP-ESICM/ESAIC Study)
|
||
| Active, not recruiting |
NCT04918901 -
Comparative Analysis of Clinical Parameters and Radiographic Changes of Severe COVID-19
|
||
| Recruiting |
NCT05233605 -
Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
|
||
| Not yet recruiting |
NCT04613986 -
Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19
|
N/A | |
| Recruiting |
NCT05447013 -
Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT04733833 -
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
|
Phase 2 | |
| Recruiting |
NCT04712344 -
Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)
|
Phase 2 | |
| Terminated |
NCT04713176 -
Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients
|
Phase 3 | |
| Recruiting |
NCT04648410 -
Corticosteroids in Severe COVID-19(ASAP-C Study)
|
||
| Enrolling by invitation |
NCT06235866 -
Risk Identification of Long-term Complications
|
||
| Recruiting |
NCT05254990 -
Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
|
Phase 3 |